Menu Search
Equities

Alpha Teknova Inc

TKNO:NMQ

Alpha Teknova Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.38
  • Today's Change-1.18 / -15.61%
  • Shares traded467.93k
  • 1 Year change+227.18%
  • Beta0.3879
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Alpha Teknova Inc had revenues fall -11.43% from 41.42m to 36.68m, though the company grew net income from a loss of 47.47m to a smaller loss of 36.78m.
Gross margin22.38%
Net profit margin-98.08%
Operating margin-95.96%
Return on assets-27.65%
Return on equity-41.51%
Return on investment-32.36%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Alpha Teknova Inc fell by 13.75m. Cash Flow from Financing totalled 12.80m or 34.89% of revenues. In addition the company used 18.81m for operations while cash used for investing totalled 7.74m.
Cash flow per share-0.7325
Price/Cash flow per share--
Book value per share1.93
Tangible book value per share1.60
More ▼

Balance sheet in USDView more

Alpha Teknova Inc has a Debt to Total Capital ratio of 14.40%.
Current ratio4.76
Quick ratio3.28
Total debt/total equity0.1683
Total debt/total capital0.144
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.